JAK2 JH2 Domain (V617F, W659A, W777A, F794H mutant, human, r

JAK2 is a non-receptor tyrosine kinase that has roles in immune signaling.1,2 It is composed of N-terminal FERM and SH2 domains, a regulatory JH2 pseudokinase domain, and a C-terminal JH1 kinase domain. It is widely expressed and associates with class I and class II cytokine receptors at the plasma membrane.3,4 Activation of these cytokine receptors activates JAK2 and induces its dimerization and kinase activity, leading to JAK2 phosphorylation of STAT transcription factors and transcription of immune-related target genes. JAK2 signaling is inhibited by the suppressor of cytokine signaling (SOCS) proteins SOCS1 and SOCS3.5,6 Mutagenesis of the JAK2 JH2 domain to contain W659A, W777A, and F794H mutations and truncation at Asp812 increases the solubility of recombinant wild-type JAK2 and JAK2V617F.7 Gain-of-function mutations in JAK2, such as JAK2V617F in the JH2 domain, are associated with various blood disorders, including leukemias and myeloproliferative neoplasms.4 Cayman's JAK2 JH2 Domain (V617F, W659A, W777A, F794H mutant, human, recombinant, aa 536-812) protein can be used for binding assays and has a calculated molecular weight of 33 kDa. WARNING This product is not for human or veterinary use. Purity: >90% estimated by SDS-PAGE. Source: Active recombinant human C-terminal His-tagged JAK2 (V617F, W659A, W777A, F794H mutant) JH2 domain expressed in insect cells (Sf9). Amino Acids: 536-812. MW: 33 kDa. Formulation: 40 mM Tris-HCl, pH 8.0, with 110 mM sodium chloride, 2.2 mM potassium chloride, 0.5 mM TCEP, and 20% glycerol.